PALO ALTO, Calif.--(BUSINESS WIRE)--StemCells, Inc. (NASDAQ: STEM) today announced that Stephen Huhn, M.D., F.A.C.S., F.A.A.P., has accepted a position as Vice President and Head of the Neural Program, effective January 1. Dr. Huhn will be on leave from his positions as Associate Professor of Neurosurgery and Chief of Pediatric Neurosurgery at Stanford University School of Medicine. As a consultant to the Company, Dr. Huhn was instrumental in the design of the protocol for the Company’s clinical trial of its proprietary human neural stem cell product, HuCNS-SC™, in Batten disease now being conducted at Oregon Health & Science University in Portland, Oregon.
